Collegium Pharmaceutical, Inc. (COLL) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income $3.70M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income $30.90M; Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA (m); Operating income $60.76M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income $62.09M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | $3.70M | (m) | $199.88M | (m) | $496.00K* | $71.32M* | $89.59M | (m) | $106.59M | $1.52M |
| 2026-03-31 | Reported | (m) | $30.90M | (m) | $193.52M | (m) | $270.00K | $57.11M | $76.27M | (m) | $86.35M | $4.24M |
| 2025-12-31 | Reported | (m) | $60.76M | (m) | $205.45M | (m) | (m) | (m) | $77.07M | (m) | $67.64M | $12.07M |
| 2025-09-30 | Reported | (m) | $62.09M | (m) | $209.36M | (m) | $188.00K* | $78.44M* | $80.19M | (m) | $67.10M | $11.93M |
| 2025-06-30 | Reported | (m) | $35.10M | (m) | $188.00M | (m) | $65.00K* | $72.44M* | $79.62M | (m) | $73.64M | $5.04M |
| 2025-03-31 | Reported | (m) | $21.69M | (m) | $177.76M | (m) | $798.00K | $55.40M | $80.43M | (m) | $76.42M | $705.00K |
| 2024-12-31 | Reported | (m) | $38.11M | (m) | $181.95M | (m) | (m) | (m) | $83.66M | (m) | $63.09M | $4.73M |
| 2024-09-30 | Reported | (m) | $34.84M | (m) | $159.30M | (m) | $244.00K* | -$9.00M* | $62.51M | (m) | $61.95M | $6.25M |
| 2024-06-30 | Reported | (m) | $47.47M | (m) | $145.28M | (m) | $270.00K* | $67.40M* | $54.47M | (m) | $43.34M | $9.49M |
| 2024-03-31 | Reported | (m) | $49.47M | (m) | $144.92M | (m) | $568.00K | $61.94M | $53.47M | (m) | $41.98M | $8.91M |
| 2023-12-31 | Reported | (m) | $61.69M | (m) | $149.75M | (m) | (m) | (m) | $55.12M | (m) | $32.94M | $14.77M |
| 2023-09-30 | Reported | (m) | $45.01M | (m) | $136.71M | (m) | $65.00K* | $74.02M* | $56.40M | (m) | $35.30M | $8.15M |
| 2023-06-30 | Reported | (m) | $35.63M | (m) | $135.55M | (m) | $56.00K* | $99.72M* | $61.72M | (m) | $38.19M | $4.79M |
| 2023-03-31 | Reported | (m) | $24.63M | (m) | $144.77M | (m) | $176.00K | $27.67M | $67.36M | (m) | $52.77M | -$131.00K |
| 2022-12-31 | Reported | (m) | $11.76M | (m) | $129.62M | (m) | (m) | (m) | $79.83M | (m) | $38.03M | -$592.00K |
| 2022-09-30 | Reported | (m) | $20.47M | (m) | $127.01M | (m) | $113.00K* | $42.77M* | $68.17M | $0.00* | $38.37M | $975.00K |
| 2022-06-30 | Reported | (m) | $11.11M | (m) | $123.55M | (m) | $461.00K* | $40.45M* | $71.19M | $0.00 | $41.25M | -$1.46M |
| 2022-03-31 | Reported | (m) | -$10.02M | (m) | $83.75M | (m) | $108.00K | -$25.32M | $35.26M | $0.00 | $54.53M | -$2.77M |
| 2021-12-31 | Reported | (m) | -$34.12M | (m) | $27.36M | (m) | (m) | (m) | $28.70M | $1.61M | $26.60M | -$13.84M |
| 2021-09-30 | Reported | (m) | $14.15M | (m) | $78.84M | (m) | $276.00K* | $17.25M* | $32.73M | $1.45M | $30.51M | $991.00K |
| 2021-06-30 | Reported | (m) | $16.41M | (m) | $82.94M | (m) | $725.00K* | $29.54M* | $32.70M | $3.46M | $30.37M | -$61.85M |
| 2021-03-31 | Reported | (m) | $21.19M | (m) | $87.72M | (m) | $428.00K | $20.57M | $32.12M | $2.93M | $31.48M | -$188.00K |
| 2020-12-31 | Reported | (m) | $15.00M | (m) | $76.27M | (m) | (m) | (m) | $31.98M | $2.47M | $26.82M | $304.00K |
| 2020-09-30 | Reported | $19.82M* | $19.63M | $195.00K* | $79.18M | 25.03%* | $2.40M* | $34.18M* | $30.98M | $2.14M | $26.43M | $280.00K |
| 2020-06-30 | Reported | $16.75M* | $16.55M | $196.00K* | $78.06M | 21.45%* | $826.00K* | $43.85M* | $29.69M | $2.49M | $29.32M | $246.00K |
| 2020-03-31 | Reported | (m) | (m) | (m) | (m) | 6.87% | $836.00K | -$6.67M | $37.52M | $2.67M | $31.26M | $246.00K |
| 2019-12-31 | Reported | (m) | (m) | (m) | (m) | -2.93% | (m) | (m) | $49.09M | $2.40M | $25.09M | (m) |
| 2019-09-30 | Reported | -$6.20M* | -$6.38M | $180.00K* | $72.94M | -8.49%* | $1.35M* | $6.07M* | $46.75M | $2.49M | $30.07M | $0.00 |
| 2019-06-30 | Reported | -$4.84M* | -$5.01M | $171.00K* | $75.04M | -6.45%* | $875.00K* | $14.63M* | $48.65M | $2.46M | $28.93M | (m) |
| 2019-03-31 | Reported | (m) | (m) | (m) | (m) | -13.16% | $3.32M | -$8.57M | $49.16M | $2.99M | $32.35M | (m) |
| 2018-12-31 | Reported | (m) | (m) | (m) | (m) | 15.45% | (m) | (m) | $29.73M | $2.25M | $30.45M | (m) |
| 2018-09-30 | Reported | -$11.03M* | -$11.19M | $154.00K* | $70.18M | -15.72%* | $2.72M* | $41.83M* | $46.01M | $1.91M | $33.45M | (m) |
| 2018-06-30 | Reported | -$7.20M* | -$7.29M | $96.00K* | $73.06M | -9.85%* | $631.00K* | $55.60M* | $46.84M | $2.24M | $31.28M | (m) |
| 2018-03-31 | Reported | (m) | (m) | (m) | (m) | -19.96% | $356.00K | $29.66M | $43.11M | $2.27M | $31.58M | (m) |
| 2017-12-31 | Reported | (m) | (m) | (m) | (m) | -161.69% | (m) | (m) | $1.09M | $2.19M | $25.09M | (m) |
| 2017-09-30 | Reported | -$13.30M* | -$13.43M | $132.00K* | $11.95M | -111.28%* | $340.00K* | -$12.57M* | $553.00K | $2.07M | $22.76M | (m) |
| 2017-06-30 | Reported | -$21.13M* | -$21.26M | $124.00K* | $3.56M | -593.65%* | $449.00K* | -$17.47M* | $577.00K | $2.18M | $22.06M | (m) |
| 2017-03-31 | Reported | (m) | (m) | (m) | (m) | -1057.46% | $29.00K | -$23.69M | $371.00K | $2.13M | $22.85M | (m) |
| 2016-12-31 | Reported | (m) | -$27.58M | (m) | (m) | (m) | (m) | (m) | (m) | $3.33M | $25.37M | (m) |
| 2016-09-30 | Reported | -$26.17M* | -$26.44M | $273.00K* | (m) | (m) | $111.00K* | (m) | (m) | $3.25M | $23.57M | (m) |
| 2016-06-30 | Reported | -$24.43M* | -$24.47M | $44.00K* | (m) | (m) | (m) | (m) | (m) | $4.30M | $20.17M | (m) |
| 2016-03-31 | Reported | -$15.54M* | -$15.59M | $43.00K | (m) | (m) | (m) | (m) | (m) | $4.06M | $11.53M | (m) |
| 2015-12-31 | Reported | (m) | -$9.44M | (m) | (m) | (m) | (m) | (m) | (m) | $1.53M | (m) | (m) |
| 2015-09-30 | Reported | -$9.23M* | -$9.27M | $38.00K* | (m) | (m) | $152.00K* | (m) | (m) | $3.36M | $5.91M | (m) |
| 2015-06-30 | Reported | -$4.53M* | -$4.58M | $46.00K* | (m) | (m) | (m) | (m) | (m) | $1.64M | (m) | (m) |
| 2015-03-31 | Reported | -$3.58M* | -$3.63M | $46.00K | (m) | (m) | (m) | (m) | (m) | $1.45M | (m) | (m) |
| 2014-12-31 | Reported | (m) | -$3.33M | (m) | (m) | (m) | (m) | (m) | (m) | $2.31M | (m) | (m) |
| 2014-09-30 | Reported | (m) | -$6.50M | (m) | (m) | (m) | (m) | (m) | (m) | $5.82M | (m) | (m) |
| 2014-06-30 | Reported | (m) | -$4.09M | (m) | (m) | (m) | (m) | (m) | (m) | $3.56M | (m) | (m) |
| 2014-03-31 | Reported | (m) | -$3.75M | (m) | (m) | (m) | (m) | (m) | (m) | $3.27M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Rolling | (m) | $157.44M* | (m) | $808.21M* | (m) | (m) | (m) | $323.12M* | (m) | $327.69M* | $29.77M* |
| 2026-03-31 | Rolling | (m) | $188.84M* | (m) | $796.33M* | (m) | (m) | (m) | $313.15M* | (m) | $294.73M* | $33.29M* |
| 2025-12-31 | Reported | (m) | $179.64M | (m) | $780.57M | (m) | $1.74M | $329.32M | $317.31M | (m) | $284.80M | $29.75M |
| 2025-12-31 | Rolling | (m) | $179.64M* | (m) | $780.57M* | (m) | (m) | (m) | $317.31M* | (m) | $284.80M* | $29.75M* |
| 2025-09-30 | Rolling | (m) | $156.99M* | (m) | $757.07M* | (m) | (m) | (m) | $323.90M* | (m) | $280.25M* | $22.41M* |
| 2025-06-30 | Rolling | (m) | $129.74M* | (m) | $707.01M* | (m) | (m) | (m) | $306.22M* | (m) | $275.11M* | $16.73M* |
| 2025-03-31 | Rolling | (m) | $142.11M* | (m) | $664.28M* | (m) | (m) | (m) | $281.07M* | (m) | $244.80M* | $21.17M* |
| 2024-12-31 | Reported | (m) | $169.90M | (m) | $631.45M | (m) | $1.65M | $204.98M | $254.10M | $0.00 | $210.36M | $29.38M |
| 2024-12-31 | Rolling | (m) | $169.90M* | (m) | $631.45M* | (m) | (m) | (m) | $254.10M* | (m) | $210.36M* | $29.38M* |
| 2024-09-30 | Rolling | (m) | $193.47M* | (m) | $599.25M* | (m) | (m) | (m) | $225.56M* | (m) | $180.21M* | $39.41M* |
| 2024-06-30 | Rolling | (m) | $203.65M* | (m) | $576.65M* | (m) | (m) | (m) | $219.45M* | (m) | $153.56M* | $41.32M* |
| 2024-03-31 | Rolling | (m) | $191.81M* | (m) | $566.92M* | (m) | (m) | (m) | $226.70M* | (m) | $148.41M* | $36.62M* |
| 2023-12-31 | Reported | (m) | $166.96M | (m) | $566.77M | (m) | $461.00K | $274.75M | $240.60M | $0.00 | $159.21M | $27.58M |
| 2023-12-31 | Rolling | (m) | $166.96M* | (m) | $566.77M* | (m) | (m) | (m) | $240.60M* | (m) | $159.21M* | $27.58M* |
| 2023-09-30 | Rolling | (m) | $117.03M* | (m) | $546.64M* | (m) | (m) | (m) | $265.31M* | (m) | $164.30M* | $12.22M* |
| 2023-06-30 | Rolling | (m) | $92.48M* | (m) | $536.95M* | (m) | (m) | (m) | $277.09M* | (m) | $167.37M* | $5.04M* |
| 2023-03-31 | Rolling | (m) | $67.96M* | (m) | $524.95M* | (m) | (m) | (m) | $286.56M* | (m) | $170.43M* | -$1.20M* |
| 2022-12-31 | Reported | (m) | $33.32M | (m) | $463.93M | (m) | $1.62M | $124.23M | $254.44M | $3.98M | $172.19M | -$3.85M |
| 2022-12-31 | Rolling | (m) | $33.32M* | (m) | $463.93M* | (m) | (m) | (m) | $254.44M* | (m) | $172.19M* | -$3.85M* |
| 2022-09-30 | Rolling | (m) | -$12.56M* | (m) | $361.68M* | (m) | (m) | (m) | $203.31M* | $1.61M* | $160.76M* | -$17.09M* |
| 2022-06-30 | Rolling | (m) | -$18.88M* | (m) | $313.50M* | (m) | (m) | (m) | $167.87M* | $3.06M* | $152.90M* | -$17.08M* |
| 2022-03-31 | Rolling | (m) | -$13.58M* | (m) | $272.90M* | (m) | (m) | (m) | $129.38M* | $6.52M* | $142.01M* | -$77.48M* |
| 2021-12-31 | Reported | (m) | $17.63M | (m) | $276.87M | (m) | $1.94M | $103.56M | $126.25M | $9.45M | $118.96M | -$74.89M |
| 2021-12-31 | Rolling | (m) | $17.63M* | (m) | $276.87M* | (m) | (m) | (m) | $126.25M* | $9.45M* | $118.96M* | -$74.89M* |
| 2021-09-30 | Rolling | (m) | $66.75M* | (m) | $325.78M* | (m) | (m) | (m) | $129.53M* | $10.31M* | $119.18M* | -$60.74M* |
| 2021-06-30 | Rolling | (m) | $72.22M* | (m) | $326.11M* | (m) | (m) | (m) | $127.79M* | $11.01M* | $115.09M* | -$61.46M* |
| 2021-03-31 | Rolling | (m) | $72.36M* | (m) | $321.23M* | (m) | (m) | (m) | $124.78M* | $10.04M* | $114.05M* | $642.00K* |
| 2020-12-31 | Reported | (m) | $56.23M | (m) | $310.02M | (m) | $5.55M | $93.94M | $130.18M | $9.77M | $113.83M | $830.00K |
| 2020-12-31 | Rolling | (m) | $56.23M* | (m) | $310.02M* | (m) | (m) | (m) | $130.18M* | $9.77M* | $113.83M* | $1.08M* |
| 2020-09-30 | Rolling | (m) | $38.86M* | (m) | $307.95M* | (m) | (m) | (m) | $147.29M* | $9.70M* | $112.10M* | (m) |
| 2020-06-30 | Rolling | (m) | $12.86M* | (m) | $301.71M* | (m) | (m) | (m) | $163.06M* | $10.05M* | $115.74M* | (m) |
| 2020-03-31 | Rolling | (m) | -$8.70M* | (m) | $298.70M* | (m) | (m) | (m) | $182.02M* | $10.01M* | $115.36M* | (m) |
| 2019-12-31 | Reported | (m) | (m) | (m) | (m) | -7.76% | $6.44M | $27.78M | $193.66M | $10.34M | $116.45M | $0.00 |
| 2019-12-31 | Rolling | (m) | -$23.75M* | (m) | $296.70M* | (m) | (m) | (m) | $193.66M* | $10.34M* | $116.45M* | (m) |
| 2019-09-30 | Rolling | (m) | -$10.37M* | (m) | $295.93M* | (m) | (m) | (m) | $174.30M* | $10.19M* | $121.81M* | (m) |
| 2019-06-30 | Rolling | (m) | -$15.19M* | (m) | $293.16M* | (m) | (m) | (m) | $173.55M* | $9.61M* | $125.19M* | (m) |
| 2019-03-31 | Rolling | (m) | -$17.47M* | (m) | $291.18M* | (m) | (m) | (m) | $171.74M* | $9.38M* | $127.53M* | (m) |
| 2018-12-31 | Reported | (m) | (m) | (m) | (m) | -6.99% | $5.48M | $169.39M | $165.68M | $8.66M | $126.76M | (m) |
| 2018-12-31 | Rolling | (m) | -$20.68M* | (m) | $280.41M* | (m) | (m) | (m) | $165.68M* | $8.66M* | $126.76M* | (m) |
| 2018-09-30 | Rolling | (m) | -$49.27M* | (m) | $217.78M* | (m) | (m) | (m) | $137.04M* | $8.61M* | $121.40M* | (m) |
| 2018-06-30 | Rolling | (m) | -$51.51M* | (m) | $159.55M* | (m) | (m) | (m) | $91.59M* | $8.77M* | $110.71M* | (m) |
| 2018-03-31 | Rolling | (m) | -$65.48M* | (m) | $90.05M* | (m) | (m) | (m) | $45.33M* | $8.71M* | $101.49M* | (m) |
| 2017-12-31 | Reported | (m) | (m) | (m) | (m) | -262.86% | $990.00K | -$67.02M | $2.60M | $8.57M | $92.76M | (m) |
| 2017-12-31 | Rolling | (m) | -$75.45M* | (m) | $28.48M* | (m) | (m) | (m) | $2.60M* | $8.57M* | $92.76M* | (m) |
| 2017-09-30 | Rolling | (m) | -$85.44M* | (m) | (m) | (m) | (m) | (m) | (m) | $9.71M* | $93.03M* | (m) |
| 2017-06-30 | Rolling | (m) | -$98.45M* | (m) | (m) | (m) | (m) | (m) | (m) | $10.89M* | $93.84M* | (m) |
| 2017-03-31 | Rolling | (m) | -$101.67M* | (m) | (m) | (m) | (m) | (m) | (m) | $13.02M* | $91.95M* | (m) |
| 2016-12-31 | Reported | (m) | (m) | (m) | (m) | -5460.37% | $477.00K | -$75.05M | $213.00K | $14.95M | $80.63M | (m) |
| 2016-12-31 | Rolling | (m) | -$94.08M* | (m) | (m) | (m) | (m) | (m) | (m) | $14.95M* | $80.63M* | (m) |
| 2016-09-30 | Rolling | (m) | -$75.94M* | (m) | (m) | (m) | (m) | (m) | (m) | $13.15M* | (m) | (m) |
| 2016-06-30 | Rolling | (m) | -$58.76M* | (m) | (m) | (m) | (m) | (m) | (m) | $13.25M* | (m) | (m) |
| 2016-03-31 | Rolling | (m) | -$38.86M* | (m) | (m) | (m) | (m) | (m) | (m) | $10.59M* | (m) | (m) |
| 2015-12-31 | Reported | -$26.74M* | -$26.91M | $171.00K | (m) | (m) | $362.00K | -$21.57M | (m) | $7.97M | $18.93M | (m) |
| 2015-12-31 | Rolling | (m) | -$26.91M* | (m) | (m) | (m) | (m) | (m) | (m) | $7.97M* | (m) | (m) |
| 2015-09-30 | Rolling | (m) | -$20.80M* | (m) | (m) | (m) | (m) | (m) | (m) | $8.75M* | (m) | (m) |
| 2015-06-30 | Rolling | (m) | -$18.04M* | (m) | (m) | (m) | (m) | (m) | (m) | $11.21M* | (m) | (m) |
| 2015-03-31 | Rolling | (m) | -$17.55M* | (m) | (m) | (m) | (m) | (m) | (m) | $13.13M* | (m) | (m) |
| 2014-12-31 | Reported | -$17.48M* | -$17.66M | $187.00K | (m) | (m) | $8.00K | (m) | (m) | $14.96M | $2.71M | (m) |
| 2014-12-31 | Rolling | (m) | -$17.66M* | (m) | (m) | (m) | (m) | (m) | (m) | $14.96M* | (m) | (m) |
| 2013-12-31 | Reported | (m) | -$16.04M | (m) | (m) | (m) | $206.00K | (m) | (m) | $14.16M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |